WuXi be­came a crit­i­cal part­ner to bio­phar­ma com­pa­nies. They’re not ready if the US cracks down

Last year
Deals
China

Si­lence re­ports pos­i­tive PhII cho­les­terol drug da­ta, re­veals end to Mallinck­rodt al­liance

Last year
Deals
R&D

Takeda's PhII meza­gi­ta­m­ab da­ta; Apogee's $483M raise; Gal­der­ma's IPO

Last year
News Briefing

Io­n­is touts PhII MASH study da­ta that fea­ture its DGAT2 an­ti­sense in­hibitor

Last year
R&D

Eli Lil­ly CEO David Ricks talks Chi­na, AI, and phar­ma's next 'gold­en er­a' af­ter obe­si­ty

Last year
Pharma

Sanofi to shut­ter ex-Kymab R&D fa­cil­i­ty in the UK

Last year
People
R&D

No­var­tis re­turns for an­oth­er piece of IFM Ther­a­peu­tics

Last year
Deals
Pharma

Ex­clu­sive: ‘Chat­G­PT for DNA’: Re­la­tion nabs $35M, with Nvidia back­ing, for os­teo­poro­sis work

Last year
Financing
Startups

Cri­net­ics’ car­ci­noid syn­drome drug gears up for reg­is­tra­tional test af­ter PhII da­ta up­date

Last year
R&D

Eli Lil­ly taps Ama­zon Phar­ma­cy to dis­pense its pre­scrip­tion med­i­cines

Last year
Marketing
Health Tech

FDA chal­lenges safe­ty, ef­fi­ca­cy of Geron's ime­tel­stat ahead of ad­vi­so­ry com­mit­tee meet­ing

Last year
Pharma
FDA+

Madri­gal to grap­ple with lack of aware­ness about NASH ahead of po­ten­tial FDA ap­proval

Last year
Pharma
Marketing

US spent $3B on DMD treat­ments as con­fir­ma­to­ry stud­ies still un­der­way, JA­MA pa­per says

Last year
Pharma
FDA+

Topline Ad­cetris da­ta in blood can­cer could mean new in­di­ca­tion for Pfiz­er

Last year
R&D
Pharma

Take­da trims op­er­a­tions at Aus­tri­an site, lays off 190 staffers

Last year
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er, Lil­ly lead Acad­e­my Awards phar­ma ads; Merz Aes­thet­ics teams with De­mi Lo­va­to

Last year
Pharma
Marketing

From Tik­Tok to the Os­cars: How mar­ket­ing obe­si­ty drugs is no longer just the purview of Eli Lil­ly and No­vo Nordisk

Last year
Marketing

Roche is try­ing again and again in Alzheimer’s. This time, ear­ly da­ta are ‘worth watch­ing’

Last year
R&D

Reg­u­lus rais­es $100M; Can­cer com­pa­ny files to go pub­lic

Last year
News Briefing

Bris­tol My­ers drops an­oth­er Cy­tomX pro­gram

Last year
R&D

The R&D 15: Top phar­ma play­ers shell out record $153B for re­search, and M&A is a prime fo­cus for all

Last year
Bioregnum
R&D

Mer­ck pens pact with Pearl Bio for new bi­o­log­ics in can­cer

Last year
Startups
Deals

Ex-The­seus ex­ecs ex­tend GIST mis­sion by tak­ing helm of IDRx

Last year
People

As place­bo spoils PhI­II tri­al, Aca­dia does not in­tend to stage fur­ther Nu­plazid stud­ies in schiz­o­phre­nia

Last year
R&D
First page Previous page 186187188189190191192 Next page Last page
A service from the Financial Times